Please login to the form below

Not currently logged in
Email:
Password:

eluxadoline

This page shows the latest eluxadoline news and features for those working in and with pharma, biotech and healthcare.

NICE backs Allergan's IBS therapy Truberzi

NICE backs Allergan's IBS therapy Truberzi

Truberzi (eluxadoline) is the only drug licensed for IBS-D in Europe and was approved by the EMA last year based on data from two pivotal trials which revealed the drug ... Eluxadoline works by stimulating to mu and kappa opioid receptors in the

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    Furiex/ Forest Labs. Acquisition. IBS, eluxadoline, a mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of IBD (NDA-ready).

  • Pharma deals during April 2014 Pharma deals during April 2014

    main focus of the deal, the drug eluxadoline, receive FDA approval and is not scheduled as a controlled drug. ... Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....